<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Anti-IgE therapy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Anti-IgE therapy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Anti-IgE therapy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeff Stokes, MD, FAAAAI, FACAAI
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Thomas B Casale, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jonathan Corren, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anna M Feldweg, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 29, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immunoglobulin E (IgE) plays a central role in the pathogenesis of allergic diseases, including asthma [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         This review will examine IgE neutralization therapy with anti-IgE monoclonal antibody, with a focus on the treatment of asthma. Other promising approaches to reducing IgE, as well as investigational applications of anti-IgE to other disorders, will be discussed briefly.
        </p>
        <p>
         The role of anti-IgE therapy in the overall management of asthma, as recommended by national and international asthma guidelines, is presented separately. The use of anti-IgE in the management of chronic spontaneous urticaria is also discussed in greater detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/547.html" rel="external">
          "An overview of asthma management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8111.html" rel="external">
          "Chronic spontaneous urticaria: Treatment of refractory symptoms", section on 'Omalizumab'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          ROLE OF IgE IN ASTHMA
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most asthmatic patients have elevated circulating IgE concentrations when levels are adjusted for age [
         <a href="#rid2">
          2
         </a>
         ]. Allergic sensitization results from the formation of specific IgE in response to common inhalant allergens, such as those derived from house dust mites, pollens, animal dander, molds, and cockroaches.
        </p>
        <p class="headingAnchor" id="H8420595">
         <span class="h2">
          Production and functions of IgE
         </span>
         <span class="headingEndMark">
          —
         </span>
         IgE is produced by B lymphocytes under the direction of two cytokines: interleukin (IL)-4 and the closely related IL-13, which are produced by several cell types including T helper type 2 (Th2) cells (a subset of T helper lymphocytes prevalent in atopy) [
         <a href="#rid3">
          3,4
         </a>
         ]. IgE formation is markedly enhanced by the interaction of two costimulatory molecules: CD40 ligand expressed on Th2 cells and CD40 expressed on B cells. Appropriately stimulated B cells mature into plasma cells that secrete allergen-specific IgE, which circulates and binds to high-affinity receptors (Fc-epsilon-RI) on the surface of mast cells, basophils, and other cells. (See
         <a class="medical medical_review" href="/z/d/html/3981.html" rel="external">
          "Mast cells: Surface receptors and signal transduction", section on 'High-affinity IgE receptor'
         </a>
         .)
        </p>
        <p>
         Bridging of IgE molecules on mast cells and basophils by protein allergens results in the activation of these cells. Activation leads to release of preformed mediators, such as histamine, and increased synthesis of lipid mediators, such as prostaglandins and cysteinyl-leukotrienes, which in turn results in bronchoconstriction and plasma exudation [
         <a href="#rid5">
          5
         </a>
         ]. Subsequently, mast cells and basophils synthesize and release a number of cytokines important in allergic inflammation. Thus, IgE plays a central role in the mechanism of immediate bronchoconstriction and the late inflammatory response after allergen inhalation challenge of allergic asthmatic subjects. (See
         <a class="medical medical_review" href="/z/d/html/5542.html" rel="external">
          "The biology of IgE"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83038.html" rel="external">
          "The relationship between IgE and allergic disease"
         </a>
         .)
        </p>
        <p>
         Circulating IgE also binds to high-affinity receptors on dendritic cells and to low-affinity IgE receptors (Fc-epsilon-RII or CD23) found on B lymphocytes, monocytes, macrophages, and dendritic cells [
         <a href="#rid6">
          6
         </a>
         ]. Allergen may also interact with bound IgE on these cells, although higher concentrations of allergenic proteins may be required to result in cell activation.
        </p>
        <p>
         Atopy is the strongest risk factor for developing asthma [
         <a href="#rid2">
          2,7,8
         </a>
         ]. Up to 80 percent of asthmatic patients in the United States and other developed countries are atopic, with one or more positive skin tests to common allergens and detectable allergen-specific IgE concentrations in serum [
         <a href="#rid9">
          9,10
         </a>
         ]. Exposure to allergens to which patients are sensitive can lead to acute and chronic asthma symptoms. A small proportion of asthmatic patients have "intrinsic" asthma with negative skin tests, normal levels of total IgE, and no circulating specific IgE. Others lose their atopic status over time but not their asthma. However, some of these patients may have local mucosal formation of IgE or may have IgE directed against unrecognized environmental allergens, suggesting that IgE may be abnormal in nearly all asthmatic patients, irrespective of whether they are atopic [
         <a href="#rid11">
          11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/572.html" rel="external">
          "Risk factors for asthma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/522.html" rel="external">
          "Pathogenesis of asthma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Effects of other therapies on IgE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Glucocorticoids do not inhibit IgE synthesis by B lymphocytes and may even increase circulating IgE by enhancing the expression of CD40 ligand [
         <a href="#rid12">
          12,13
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3986.html" rel="external">
          "Glucocorticoid effects on the immune system", section on 'B cells and immunoglobulin levels'
         </a>
         .)
        </p>
        <p>
         Immunotherapy is an option for patients with allergic asthma. Subcutaneous immunotherapy is associated with significant risk of systemic reactions in those with moderate-to-severe persistent asthma. However, immunotherapy should be considered in some atopic patients with clear allergic triggers. Successful immunotherapy is associated with a suppression of the usual postseasonal rise in allergen-specific IgE. In some countries, sublingual immunotherapy is preferred for patients with asthma, as the risk of anaphylaxis is less than for injection immunotherapy. (See
         <a class="medical medical_review" href="/z/d/html/361.html" rel="external">
          "Subcutaneous immunotherapy (SCIT) for allergic rhinoconjunctivitis and asthma: Indications and efficacy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7765588">
         <span class="h1">
          OMALIZUMAB THERAPY IN ASTHMA
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          Omalizumab
         </a>
         is a recombinant humanized IgG1 monoclonal antibody that binds IgE with high affinity and has been developed for the treatment of allergic diseases [
         <a href="#rid14">
          14-17
         </a>
         ]. Omalizumab is the only available anti-IgE therapy in use. (See
         <a class="local">
          'Other novel strategies to reduce IgE'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H7764932">
         <span class="h2">
          Indications and patient selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the United States and many other countries where it is available,
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         is approved for use in patients with
         <strong>
          all
         </strong>
         of the following characteristics [
         <a href="#rid18">
          18,19
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Six years of age and older.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Moderate-to-severe persistent asthma (in the United States).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Asthma symptoms that are inadequately controlled with inhaled glucocorticoids (in the United Kingdom, patients must have symptoms despite
         <strong>
          high
         </strong>
         doses of inhaled glucocorticoids).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A total serum IgE level between 30 and 700 (1300 for children 6 to 11 years old and 1500 in Europe) international units/mL, which is the range over which the drug can reduce enough free IgE to ensure a therapeutic effect, provided the patient's body weight is within a specified range. (See
         <a class="local">
          'Mechanisms of action'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Allergic sensitization demonstrated by positive skin testing or in vitro testing for allergen-specific IgE to an allergen that is present year-round (a perennial allergen), such as house dust mites, animal danders, cockroaches, or molds.
        </p>
        <p>
        </p>
        <p>
         The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fginasthma.org%2Fgina-reports%2F&amp;token=Py93ynnU9f3vyGk1a5XWKiW%2FmuhscuPY09dfrBoFhX2Q3GzgeLrGYBihxgI54Axy&amp;TOPIC_ID=545" target="_blank">
          2021 Global Initiative for Asthma (GINA) guidelines
         </a>
         recommended
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         for patients with moderate or severe allergic asthma uncontrolled on step 4 to 5 treatment. (See
         <a class="medical medical_review" href="/z/d/html/551.html" rel="external">
          "Treatment of severe asthma in adolescents and adults", section on 'Anti-IgE therapy (omalizumab)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7765369">
         <span class="h3">
          Predictors of response
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among patients who meet all of the criteria for approved use, there are limited characteristics that predict a positive response to
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         , although preliminary findings suggest a pretreatment circulating eosinophil count &gt;300 cells/microL may predict a better clinical response.
        </p>
        <p>
         A possible correlation between pretreatment peripheral blood eosinophil counts and response to
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         was demonstrated in some studies [
         <a href="#rid20">
          20,21
         </a>
         ]. One randomized trial included 328 patients with normal lung function aged 12 to 75 years with incompletely controlled atopic asthma despite inhaled glucocorticoids [
         <a href="#rid20">
          20
         </a>
         ]. An analysis of responses in patients with high (≥300/microL) versus low (≤300/microL) absolute peripheral eosinophil counts was planned at the study outset. The primary endpoint of the study was a reduction in the rate of asthma exacerbations during the six-month treatment period. Although the exacerbation rate was reduced in the omalizumab group compared with placebo, the difference was not statistically significant in the group as a whole, and thus, the primary endpoint was not met. However, in the high eosinophil group, the exacerbation rate was reduced by 45 percent (0.4 to 0.22 exacerbations/patient during the treatment period [95% CI 0.25-1.22]), while there was no change in the low eosinophil group. However, a real-world study did not show an enhanced effect in patients with elevated eosinophils [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         In a previous randomized trial of 1070 patients with allergic asthma performed to assess clinical predictors of responsiveness to
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         , only impaired baseline lung function or frequent exacerbations despite high-dose inhaled glucocorticoid therapy was correlated to a good response [
         <a href="#rid23">
          23
         </a>
         ]. This study did not evaluate peripheral eosinophil count as a predictor of omalizumab responsiveness.
        </p>
        <p>
         The importance of allergic triggers in a patient's disease may also be a factor, although the best means of assessing this beyond clinical history has not been determined:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A randomized trial of 419 inner-city children, adolescents, and young adults (6 to 20 years of age) found the greatest benefit in patients with allergy to prevalent indoor allergens (cockroach and dust mite) [
         <a href="#rid24">
          24
         </a>
         ]. Unexpectedly, this study also found that
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         reduced seasonal exacerbations in the fall and spring, without altering rates of positive cultures for common respiratory viruses. These findings indicate that omalizumab does not prevent viral infection, although it can alter the patient's tendency to develop an asthma exacerbation as a result of a viral infection. (See
         <a class="local">
          'Virus-induced asthma exacerbations'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with low total IgE (ie, below 30 international units/mL) who have a relatively high proportion of allergen-specific IgE also respond to
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         [
         <a href="#rid22">
          22,25,26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7765376">
         <span class="h3">
          Occupational asthma
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          Omalizumab
         </a>
         has been reported to ameliorate occupational asthma in patients who are unable to change their work environment [
         <a href="#rid27">
          27,28
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15718.html" rel="external">
          "Occupational asthma: Management, prognosis, and prevention", section on 'Management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1143720">
         <span class="h3">
          Nonatopic asthma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with nonallergic (intrinsic) asthma also have local IgE synthesis in the airways, and
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         can be beneficial in these patients as well, although it is not a treatment of choice in this subgroup because there are more appropriate therapies [
         <a href="#rid29">
          29,30
         </a>
         ]. In a small randomized trial, 18 patients with non-atopic asthma were administered omalizumab or placebo in addition to existing therapy for 20 weeks, and existing asthma medications were withdrawn in a step-wise manner after 14 weeks. Bronchial biopsies were collected at various time points. Omalizumab but not placebo therapy significantly reduced median total bronchial mucosal IgE+ cells and resulted in improvement in lung function [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4239623">
         <span class="h3">
          Virus-induced asthma exacerbations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several studies have found that
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         decreases the rate of asthma exacerbations associated with viral infections [
         <a href="#rid24">
          24,31,32
         </a>
         ]. In inner-city children with asthma and recent exacerbations, the addition of omalizumab prior to the start of school in the fall was more effective in preventing exacerbations than doubling inhaled glucocorticoids [
         <a href="#rid31">
          31
         </a>
         ]. Possible mechanisms for this effect are reviewed below. (See
         <a class="local">
          'Reduction of exacerbations related to viral infections'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Mechanisms of action
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          Omalizumab
         </a>
         binds to the third constant domain of the IgE heavy chain (C-epsilon-3), which is the same site at which IgE normally binds to both high- and low-affinity IgE receptors on mast cells, basophils, and other cell types. Thus, omalizumab forms complexes with free IgE and prevents its interaction with these receptors. The omalizumab-IgE complexes are subsequently cleared by the hepatic reticuloendothelial system  (
         <a class="graphic graphic_figure graphicRef59320" href="/z/d/graphic/59320.html" rel="external">
          figure 1
         </a>
         ). The antibody is specific to IgE and does not bind to IgG or IgA. An important property of omalizumab is that it cannot bind to IgE receptors or to IgE already attached to the alpha chain of Fc-epsilon-RI and therefore does not interact with cell-bound IgE or activate mast cells or basophils [
         <a href="#rid33">
          33
         </a>
         ]. (See
         <a class="local">
          'Hypersensitivity reactions'
         </a>
         below.)
        </p>
        <p>
         Free IgE must be reduced to extremely low levels to achieve clinical efficacy. This is because there are 10,000 to 1,000,000 Fc-epsilon-RIs on mast cells and basophils, and nearly all are occupied by IgE. Only 2000 IgE molecules are needed for half-maximal release of histamine from basophils. Therefore, a marked reduction in IgE is needed to prevent mast cell and basophil activation [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          Omalizumab
         </a>
         therapy causes a marked downregulation of Fc-epsilon-RI on the surface of basophils and mast cells, although the time course of this change may differ in the two cell types [
         <a href="#rid35">
          35-40
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of ragweed-allergic patients with allergic rhinitis, Fc-epsilon-RI on the surface of basophils was reduced by 73 percent after seven days of treatment and correlated with a decreased clinical response to allergen on nasal challenge [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In contrast, the downregulation of receptors on cutaneous mast cells occurs more slowly. In a study of dust mite-allergic patients with allergic rhinitis treated with intravenous
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         , the expression of Fc-epsilon-RI on cutaneous mast cells was unchanged after 7 days of treatment but 90 percent reduced at 70 days [
         <a href="#rid37">
          37
         </a>
         ]. The number of cells staining positive for tryptase was unchanged, demonstrating that the mast cells were still present but receptor expression had decreased. These mast cell changes correlate to a gradual reduction in cutaneous skin test responses [
         <a href="#rid37">
          37,42
         </a>
         ]. A decrement in the late-phase cutaneous response is seen by two weeks, followed by a decrease in the early phase at eight weeks of therapy [
         <a href="#rid42">
          42,43
         </a>
         ]. However, the subtlety of this reaction questions its usefulness in clinical practice.
        </p>
        <p>
        </p>
        <p>
         There is usually little to no improvement in FEV
         <sub>
          1
         </sub>
         when
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         is added to pre-existing therapy [
         <a href="#rid44">
          44,45
         </a>
         ]. Similarly, airway hyper-reactivity, as measured by
         <a class="drug drug_general" data-topicid="9622" href="/z/d/drug information/9622.html" rel="external">
          methacholine
         </a>
         responsiveness, improves little or not at all [
         <a href="#rid46">
          46,47
         </a>
         ].
        </p>
        <p>
         Several studies have demonstrated anti-inflammatory effects from
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         treatment [
         <a href="#rid47">
          47-52
         </a>
         ]. In one, bronchial biopsies show decreased eosinophils, reduced numbers of CD3+, CD4+, and CD8+ T lymphocytes, B lymphocytes, and interleukin 4-positive cells. IgE-positive cells in the bronchial mucosa were decreased 10-fold.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with moderate-to-severe asthma, treatment with
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         (compared with placebo) can decrease the incidence of exacerbations and result in a significant reduction in the dose of inhaled or oral glucocorticoids required to control symptoms [
         <a href="#rid48">
          48,49,53,54
         </a>
         ]. Omalizumab has never been compared directly in a controlled clinical trial with other asthma therapies, such as inhaled glucocorticoids with long-acting beta-agonists, antileukotriene agents, or allergen immunotherapy.
        </p>
        <p class="headingAnchor" id="H7599108">
         <span class="h3">
          Moderate-to-severe asthma
         </span>
         <span class="headingEndMark">
          —
         </span>
         A 2014 systematic review included 25 randomized trials of patients with moderate or severe asthma receiving inhaled glucocorticoids, to which subcutaneous
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         was added [
         <a href="#rid55">
          55
         </a>
         ]. Most of the studies involved patients with moderate asthma. The addition of omalizumab had the following effects:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced the risk of experiencing an exacerbation from 26 to 16 percent over 16 to 60 weeks of treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced the risk of hospitalization for asthma from 3 to 0.5 percent over 28 to 60 weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Allowed for a small but significant reduction in inhaled glucocorticoid dose (weighted mean difference -118 mcg
         <a class="drug drug_general" data-topicid="9068" href="/z/d/drug information/9068.html" rel="external">
          beclomethasone
         </a>
         dipropionate equivalent per day [95% CI -154 to -84]).
        </p>
        <p>
        </p>
        <p>
         In addition, subjects receiving
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         were significantly more likely to be able to withdraw inhaled glucocorticoids completely compared with those receiving placebo (40 versus 21 percent). However, omalizumab did not appear to increase the likelihood that subjects could discontinue
         <strong>
          oral
         </strong>
         glucocorticoids. A systematic review of three trials of children and adolescents reached similar conclusions [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7766019">
         <span class="h3">
          Severe asthma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fewer studies have been performed on patients with severe asthma (rather than moderate-to-severe) [
         <a href="#rid57">
          57,58
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a randomized trial of 850 patients (aged 12 to 75 years) with uncontrolled symptoms despite both high-dose inhaled glucocorticoids (ie, doses ≥500 mcg
         <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">
          fluticasone
         </a>
         twice daily) and long-acting beta-agonist therapy, treatment with
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         or placebo was administered for 12 months, during which other controller therapies were not changed [
         <a href="#rid57">
          57
         </a>
         ]. All patients had IgE levels within the specified range and sensitization to a perennial allergen. The primary endpoint was number of exacerbations requiring systemic glucocorticoids for more than three days or requiring an increase in daily dose of ≥20 mg of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (or equivalent) for patients on chronic oral glucocorticoids. The rates of exacerbations per subject were 0.66 and 0.88 in the omalizumab and placebo groups, respectively, which corresponded to a 25 percent reduction in the incidence rate. The difference was statistically significant. Recommendations for the treatment of severe asthma are reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/551.html" rel="external">
          "Treatment of severe asthma in adolescents and adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another study of patients with severe asthma was performed in 34 children, one-half of whom were 5 to 11 years of age [
         <a href="#rid58">
          58
         </a>
         ]. In this prospective, nonrandomized trial, consecutive children were chosen to receive four months of
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         therapy if they required daily
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         during the preceding three months. Allergy testing was not performed. Baseline serum IgE levels ranged from 119 to 1193 international units/mL (note that the higher values are outside the range approved in the United States) with a median of 411 international units/mL. Primary endpoints were reduction in prednisolone dose and changes in quality of life, Childhood Asthma Control Test (ACT), and FEV
         <sub>
          1
         </sub>
         . After four months of treatment, during which all other therapies were kept constant, 85 percent of the children were able to reduce their doses of prednisolone, with a median dose reduction from 20 mg to 5 mg daily. Dramatic reductions were seen in about 20 percent of subjects. Quality of life and ACT scores improved significantly. However, the lack of a placebo group and small size limit the conclusions that can be drawn from this study, and controlled trials are needed. Omalizumab is not approved for use in children younger than six years of age in the United States.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2886674935">
         <span class="h3">
          Reduction of exacerbations related to viral infections
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mechanism by which
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         reduces asthma exacerbations due to viral illness appears to involve the normalization of an impaired response to viral infection that can be seen in patients with asthma. In such patients, higher serum levels of IgE are associated with increasing severity of viral-induced exacerbations, and production of interferon-alpha (IFN-alpha) in response to viral infection is diminished [
         <a href="#rid59">
          59,60
         </a>
         ]. Cross-linking of IgE on the surface of plasmacytoid dendritic cells (pDCs) suppresses IFN-alpha production, which explains the relationship between exacerbation severity and serum IgE levels. Omalizumab treatment reduces free serum IgE, reduces the number of IgE receptors on the surface of pDCs (and other cell types), and augments the production of IFN-alpha by these cells in the setting of viral infection [
         <a href="#rid61">
          61
         </a>
         ]. In addition, omalizumab has been shown to decrease the duration of rhinovirus infections, viral shedding, and the risk of rhinoviral illnesses in asthmatic children [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7599115">
         <span class="h3">
          Impact on acute allergen exposures
         </span>
         <span class="headingEndMark">
          —
         </span>
         A multicenter study evaluated the effect of 16 weeks of
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         treatment on 68 patients acutely exposed to high levels of allergen in the form of a cat chamber challenge [
         <a href="#rid62">
          62
         </a>
         ]. Subjects were cat-allergic adults with moderate asthma and a history of cat-induced exacerbations, taking a mean daily dose of inhaled
         <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">
          fluticasone
         </a>
         of 340 to 380 mcg. They were randomized to omalizumab therapy or placebo and challenged in the chamber at week 0 and week 16. The primary endpoint was the area under the curve of the percentage decrease from prechallenge FEV
         <sub>
          1
         </sub>
         per hour of exposure. Patients receiving omalizumab demonstrated a significantly smaller reduction in FEV
         <sub>
          1
         </sub>
         compared with those receiving placebo (15 versus 27 percent). Both chest and nasal symptoms were also significantly lower in the treatment group, and treated patients tolerated a median of 50 minutes in the chamber, compared with 22 minutes in the placebo group.
        </p>
        <p class="headingAnchor" id="H6967462">
         <span class="h3">
          Other changes with therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following changes are typically observed during
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         treatment, although these are not considered outcomes for assessing response to treatment:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Total serum IgE levels increase three- to sixfold (due to the presence of immune complexes of
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         and IgE) and are not useful for monitoring clinical response [
         <a href="#rid11">
          11,49,63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Allergen skin testing responses are significantly reduced but are not useful as a marker of efficacy, as the inhibition is incomplete and difficult to appreciate on individual patients in a clinical setting [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Free serum IgE levels decrease dramatically, although measurement of free IgE is not available outside of research settings [
         <a href="#rid64">
          64
         </a>
         ]. One study found that free serum IgE levels did not predict clinical response to treatment with
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Therapy may also interfere with the performance of most allergen-specific IgE assays, although the ImmunoCAP system appears to retain accuracy [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blood eosinophils decreased in a study of patients with asthma [
         <a href="#rid67">
          67
         </a>
         ]. However, in a study of patients with chronic urticaria, blood eosinophils were unchanged but neutrophils were decreased [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Levels of IgG, IgA, and IgM are not affected by
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18869039">
         <span class="h2">
          Cost
         </span>
         <span class="headingEndMark">
          —
         </span>
         The cost is USD $10,000 to $12,000 per year for patients who require the minimum dose (150 mg every four weeks) and approximately USD $60,000 to $70,000 per year for those requiring the maximum dose (375 mg every two weeks), which far exceeds that of other approved asthma therapies [
         <a href="#rid18">
          18,19,69
         </a>
         ]. Several analyses have questioned the cost-effectiveness of
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         therapy [
         <a href="#rid70">
          70,71
         </a>
         ]. On the other hand, a few centers have concluded that omalizumab has a favorable cost to utility ratio in adult cohorts with severe asthma [
         <a href="#rid72">
          72-74
         </a>
         ]. In the United States, information about cost for health care providers and patients is available through the manufacturer [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Administration
         </span>
        </p>
        <p class="headingAnchor" id="H3763464096">
         <span class="h3">
          Dosing
         </span>
         <span class="headingEndMark">
          —
         </span>
         For the treatment of asthma, the dosing of
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         is weight-based (0.016 mg/kg per international units/mL of IgE per month). The dose and interval that achieves this is determined for each patient based upon body weight and the levels of serum IgE. Doses range from 150 to 375 mg injected subcutaneously every two to four weeks. Detailed dosing tables are available in the linked drug monograph on omalizumab. Therapy should
         <strong>
          not
         </strong>
         be initiated during an acute exacerbation of asthma, due to the risk of anaphylaxis. (See
         <a class="local">
          'Anaphylaxis'
         </a>
         below.)
        </p>
        <p>
         Peak serum concentration is reached in seven to eight days [
         <a href="#rid19">
          19
         </a>
         ]. A maximum amount of 150 mg should be administered at a single injection site to avoid local reactions. The elimination half-life of the drug is one to four weeks after subcutaneous administration.
        </p>
        <p>
         Dosing for the treatment of chronic spontaneous urticaria is reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/8111.html" rel="external">
          "Chronic spontaneous urticaria: Treatment of refractory symptoms", section on 'Omalizumab'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Pretreatment testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Total serum IgE levels should be between 30 and 700 international units/mL (or 1300 in children 6 to 11 years of age), although reports describe benefit in patients with IgE levels below this level, and
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         is approved above this range in Europe [
         <a href="#rid76">
          76,77
         </a>
         ]. For all patients with serum IgE levels above 300 international units/mL, there are upper limits of body weight beyond which administration is not recommended. Sensitization to a perennial aeroallergen (eg, house dust mite, animal danders, cockroaches, molds) must be demonstrated by positive skin testing or by in vitro-specific serum IgE testing. Baseline FEV
         <sub>
          1
         </sub>
         , peak flow, or other pulmonary function testing is recommended.
        </p>
        <p class="headingAnchor" id="H7765170">
         <span class="h3">
          Route of administration
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          Omalizumab
         </a>
         is approved for administration by subcutaneous injection. Initial trials demonstrated that aerosolized omalizumab was ineffective in protecting against allergen challenge and had no effect on circulating IgE [
         <a href="#rid78">
          78
         </a>
         ]. In contrast, both intravenous and subcutaneous administration induce a rapid fall in free serum IgE, although subcutaneous administration is more practical [
         <a href="#rid79">
          79-81
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1377352430">
         <span class="h3">
          Home administration
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          Omalizumab
         </a>
         may be self-administered at home in many countries, including the United States [
         <a href="#rid82">
          82
         </a>
         ]. The US Food and Drug Administration (FDA) outlined selection criteria for home administration: No prior history of anaphylaxis, successful administration of three separate doses of omalizumab in the office, ability to recognize and treat symptoms of anaphylaxis, and ability to follow the prescribed dosing regimen and utilize proper injection technique for omalizumab. Patients should be prescribed omalizumab in prefilled syringes and instructed on correct administration.
        </p>
        <p class="headingAnchor" id="H7765129">
         <span class="h3">
          Time to effect
         </span>
         <span class="headingEndMark">
          —
         </span>
         A minimum of 12 weeks of treatment is needed to determine the efficacy of anti-IgE therapy for asthma [
         <a href="#rid23">
          23
         </a>
         ]. A three- to six-month trial is appropriate, although some patients may respond only after weeks of treatment, but this appears to be atypical [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Monitoring therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         No specific laboratory tests are suggested for monitoring patients who are responding clinically to anti-IgE therapy. Total serum IgE levels increase three- to sixfold in all individuals on therapy and are not useful for monitoring clinical response [
         <a href="#rid11">
          11,49,63
         </a>
         ]. However, if therapy is interrupted for more than one year, the manufacturer states that serum IgE levels may be measured again and dosing based on the new measurement. Dosing should be adjusted for significant changes in body weight. (See
         <a class="local">
          'Other changes with therapy'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H7765080">
         <span class="h3">
          Duration of treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal duration of therapy in patients with asthma who experience clinical benefit has not been determined and consensus is lacking. Patients who respond are generally continued on the drug long term. However, if after two years the patient's asthma is well-controlled with low- to medium-dose inhaled corticosteroids, it is reasonable to extend the dosing interval gradually. Dosing should also be adjusted for changes in bodyweight.
        </p>
        <p class="headingAnchor" id="H6967598">
         <span class="h4">
          Observations post-treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         therapy is discontinued, serum-free IgE levels [
         <a href="#rid84">
          84
         </a>
         ], skin test responses [
         <a href="#rid43">
          43
         </a>
         ], and basophil surface Fc-epsilon-RI and mediator release levels [
         <a href="#rid36">
          36
         </a>
         ] gradually return to baseline.
        </p>
        <p>
         Data are accumulating to suggest that, after several years of treatment, there may be persistent benefit after the drug is discontinued [
         <a href="#rid85">
          85-87
         </a>
         ]:
        </p>
        <p>
         The largest study evaluated over 19,000 patients with asthma (2453 children older than six and 16,750 adults) who were treated with
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         for at least 16 weeks from 2009 to 2019, using the French national health care database [
         <a href="#rid85">
          85
         </a>
         ]. The median treatment period was 54 (95% CI 51-56) months in children and 51 (95% CI 49-53) months in adults. Therapy was effective, reducing rates of asthma hospitalizations by 75 percent after two years of treatment, and reducing use of oral corticosteroids by 30 percent in all ages. Among patients whose asthma was controlled during treatment, asthma remained controlled in a significant number one, two, and three years after discontinuation (ie, 76, 44, and 33 percent of children, respectively, and 70, 39, and 24 percent of adults, respectively).
        </p>
        <p>
         Thus, there appears to be lasting benefit in a significant fraction of patients who are treated with
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         for several years. A possible explanation for this observation is the effect of prolonged administration on the production of IgE. A pharmacokinetic study found that omalizumab reduced the production of IgE gradually over time, resulting in a new equilibrium after about five years [
         <a href="#rid88">
          88
         </a>
         ]. Based on the models used, the authors concluded that it could take years after discontinuation for IgE production to reach pretreatment levels. However, controlled studies are needed before recommendations can be made regarding the optimal duration of therapy.
        </p>
        <p class="headingAnchor" id="H658225490">
         <span class="h1">
          ANTI-IgE THERAPY IN OTHER DISEASES
         </span>
         <span class="headingEndMark">
          —
         </span>
         IgE plays a critical role in other allergic diseases, and it might be expected that
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         may be beneficial in the treatment of these disorders as well  (
         <a class="graphic graphic_table graphicRef104454" href="/z/d/graphic/104454.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H658225524">
         <span class="h2">
          Chronic urticaria
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          Omalizumab
         </a>
         has been shown in randomized trials to be effective for chronic spontaneous urticaria refractory to antihistamine therapy and for some forms of inducible urticaria. In 2014, omalizumab was approved in the United States for the treatment of adults and adolescents (12 years and older) with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamine treatment. The recommended dosing is different from that used for asthma. It is either 150 or 300 mg given subcutaneously every four weeks and is not determined by serum IgE level or body weight. This is reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/8111.html" rel="external">
          "Chronic spontaneous urticaria: Treatment of refractory symptoms", section on 'Omalizumab'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8102.html" rel="external">
          "Cold urticaria", section on 'Other pharmacotherapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8109.html" rel="external">
          "Physical (inducible) forms of urticaria"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H658225530">
         <span class="h2">
          Other allergic disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          Omalizumab
         </a>
         has been reported to be helpful in the management of food allergy, nasal polyposis, idiopathic anaphylaxis, allergic rhinitis, venom hypersensitivity, atopic dermatitis, and several other disorders  (
         <a class="graphic graphic_table graphicRef104454" href="/z/d/graphic/104454.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          Omalizumab
         </a>
         is approved for the treatment of chronic rhinosinusitis with nasal polyposis. (See
         <a class="medical medical_review" href="/z/d/html/121195.html" rel="external">
          "Chronic rhinosinusitis with nasal polyposis: Management and prognosis", section on 'Anti-IgE (omalizumab)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Studies have explored the use of
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         and related anti-IgE antibodies for the treatment of food allergy (including children receiving oral immunotherapy), bullous pemphigoid, asthma associated with eosinophilic granulomatosis with polyangiitis (Churg-Strauss), and allergic bronchopulmonary aspergillosis [
         <a href="#rid89">
          89-97
         </a>
         ]. Dosing in these disorders may not conform to approved standards, since some patients have extremely high IgE levels that do not fall within the ranges for recommended and approved dosing. (See
         <a class="medical medical_review" href="/z/d/html/2410.html" rel="external">
          "Experimental therapies for food allergy: Immunotherapy and nonspecific therapies", section on 'Anti-IgE'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15297.html" rel="external">
          "Management and prognosis of bullous pemphigoid", section on 'Other therapies'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4346.html" rel="external">
          "Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Treatment and prognosis", section on 'Anti-IgE therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/104431.html" rel="external">
          "Treatment of allergic bronchopulmonary aspergillosis", section on 'Anti-IgE therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121195.html" rel="external">
          "Chronic rhinosinusitis with nasal polyposis: Management and prognosis", section on 'Anti-IgE (omalizumab)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          Omalizumab
         </a>
         has been used to treat anaphylaxis in patients with idiopathic anaphylaxis, mastocytosis, and mast cell activation disorders.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          Omalizumab
         </a>
         is effective in reducing symptoms and decreasing the need for concomitant medical therapy in seasonal and perennial allergic rhinitis [
         <a href="#rid98">
          98-102
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Several reports have described the administration of
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         prior to or concomitant with subcutaneous allergen immunotherapy. Omalizumab has been administered in this manner for the purpose of reducing systemic allergic reactions to the injections in patients who were otherwise unable to tolerate immunotherapy with aeroallergens or Hymenoptera venoms [
         <a href="#rid103">
          103,104
         </a>
         ]. In addition, omalizumab added to subcutaneous immunotherapy decreases rhinitis symptoms compared with immunotherapy alone [
         <a href="#rid105">
          105
         </a>
         ]. It has also been used to help patients tolerate rapid desensitization protocols with fewer systemic allergic reactions [
         <a href="#rid105">
          105
         </a>
         ] and/or to enhance the beneficial effects of immunotherapy [
         <a href="#rid106">
          106
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4096.html" rel="external">
          "Hymenoptera venom immunotherapy: Technical issues, protocols, adverse effects, and monitoring", section on 'Recurrent systemic reactions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vernal keratoconjunctivitis in children has been successfully treated with
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         [
         <a href="#rid107">
          107
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5549.html" rel="external">
          "Vernal keratoconjunctivitis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          ADVERSE EFFECTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          Omalizumab
         </a>
         is generally well-tolerated [
         <a href="#rid54">
          54,108,109
         </a>
         ]. However, there are case reports and series of adverse reactions, including the following.
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Hypersensitivity reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypersensitivity reactions to
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         include anaphylaxis, urticaria, and injection site reactions. Severe hypersensitivity reactions to omalizumab or any ingredient of omalizumab are the only known contraindications for treatment.
        </p>
        <p class="headingAnchor" id="H7766245">
         <span class="h3">
          Anaphylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anaphylaxis and anaphylactoid reactions that could not be ascribed to any other agent developed in approximately 1 to 2 in 1000 patients receiving
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         [
         <a href="#rid110">
          110-113
         </a>
         ]. This rate of reaction is among the lowest of all biologics on the market. However, a boxed warning was added to the package insert in 2007 at the recommendation of the US Food and Drug Administration (FDA). The mechanism(s) in these reactions is not known, although a hypersensitivity reaction to the additive polysorbate 20 was implicated in a report of two cases [
         <a href="#rid114">
          114
         </a>
         ]. Skin testing with the drug was negative, and IgE or IgG antibodies specific to omalizumab were not found in any of 30 cases in another series [
         <a href="#rid115">
          115
         </a>
         ]. A self-reported history of anaphylaxis to foods, medications, or other causes has been identified as a potential risk factor.
        </p>
        <p>
         Anaphylaxis after
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         may occur after any dose. In a review of 124 cases, 39 percent occurred with the first dose, and 19 percent occurred with the second dose. The reaction occurred after one of the first three doses in 68 percent of cases [
         <a href="#rid111">
          111
         </a>
         ]. Approximately 70 percent of reported cases occurred within two hours of administration, although anaphylactic events beginning as late as four days after the injection and protracted anaphylaxis occurring over the course of one to two days have also been reported [
         <a href="#rid116">
          116,117
         </a>
         ]. A later review of 30 additional patients found that 70 percent of reactions occurred within one hour [
         <a href="#rid115">
          115
         </a>
         ].
        </p>
        <p>
         Skin testing with
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         can be performed to evaluate apparent anaphylaxis to the drug, but the predictive value has not been established. Prick testing can be performed with undiluted drug. For intradermal testing, the drug can be diluted in normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         . A concentration of 1:100,000 (1.2 micrograms/mL) has been determined to be nonirritating [
         <a href="#rid118">
          118
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h4">
          Recommended precautions
         </span>
         <span class="headingEndMark">
          —
         </span>
         A joint task force of the American Academy of Allergy, Asthma, and Immunology and the American College of Allergy, Asthma, and Immunology convened in 2007 to review the clinical trials and postmarketing surveillance data regarding anaphylaxis associated with
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         . Their report included the following recommendations for clinicians prescribing omalizumab, which could be modified at the clinician's discretion [
         <a href="#rid112">
          112
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obtain informed consent from the patient after discussing the risks, benefits, and alternatives to
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Educate the patient about the signs, symptoms, and treatment of anaphylaxis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prescribe an
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         autoinjector(s) and instruct the patient on how and when to use it. Advise the patient to bring the autoinjector to every scheduled
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         injection and carry it for at least 24 hours afterward.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assess the patient's interim health status and pulmonary function prior to each injection and withhold
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         if the patient's status might place him/her at higher risk for a more serious outcome should anaphylaxis occur (eg, an active asthma exacerbation).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Observe the patient for two hours after each of the first three injections and for 30 minutes after each subsequent injection.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H28924393">
         <span class="h4">
          Desensitization
         </span>
         <span class="headingEndMark">
          —
         </span>
         A small number of patients with omalizumab-associated allergic reactions have been desensitized. One report describes a protocol performed successfully in three patients [
         <a href="#rid119">
          119
         </a>
         ]. In another report, the patient initially tolerated
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         but later developed serum sickness [
         <a href="#rid120">
          120
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7766260">
         <span class="h3">
          Urticaria
         </span>
         <span class="headingEndMark">
          —
         </span>
         Urticaria has been reported to develop in approximately 1 percent of patients [
         <a href="#rid116">
          116
         </a>
         ]. The relationship between this limited reaction and risk for anaphylaxis has not been studied. Of note,
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         has proven to be an effective therapy for chronic spontaneous urticaria. This is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/8111.html" rel="external">
          "Chronic spontaneous urticaria: Treatment of refractory symptoms", section on 'Omalizumab'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h3">
          Injection site reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Injection site reactions appeared with equal frequency in approximately 44 percent of omalizumab- and placebo-treated patients. These were mostly described as mild-to-moderate and ranged in size from 1.5 to 3 cm. Most local reactions occurred within one hour of injection and lasted for 3 to 14 days [
         <a href="#rid108">
          108
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h3">
          Serum sickness
         </span>
         <span class="headingEndMark">
          —
         </span>
         A small number of case reports describe serum sickness-like reactions following administration [
         <a href="#rid120">
          120,121
         </a>
         ]. One case proved fatal.
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Other issues
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several other issues have arisen with continued use of
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         therapy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Unclear association with cardiovascular disease
         </strong>
         – In a 2009 safety analysis by the FDA on the Evaluating the Clinical Effectiveness and Long-term Safety in Patients with Moderate-to-Severe Asthma (EXCELS) trial, a small apparent increase was noted in certain cardiovascular disorders in patients receiving
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         compared with the placebo group [
         <a href="#rid122">
          122
         </a>
         ]. Disorders included transient ischemic attacks, cardiac ischemia, pulmonary hypertension, venous thrombosis, and pulmonary embolism. In 2014, the FDA released a statement based upon a combined analysis of 25 randomized trials comparing omalizumab with placebo, which did
         <strong>
          not
         </strong>
         detect an increased risk of thromboembolic events [
         <a href="#rid123">
          123
         </a>
         ]. However, the FDA noted that the low number of events, young population, and short duration of follow-up could have impaired the ability of the analysis to detect an increase in risk and recommended alterations in the safety labeling. A 2017 analysis of EXCELS data reported a higher incidence of cardiovascular and cerebrovascular serious adverse events in omalizumab-treated patients, compared with non-omalizumab-treated patients (13.4 versus 8.1 per 1000 patient-years), with a hazard ratio of 1.32 (95% CI, 0.91-1.91) [
         <a href="#rid124">
          124
         </a>
         ]. However, patients in the omalizumab group generally had more severe asthma than the control group. In addition, there are data indicating that asthma is a risk factor for cardiovascular disease and the more severe asthma in the omalizumab group may have confounded the results [
         <a href="#rid125">
          125
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Eosinophilic granulomatosis with polyangiitis
         </strong>
         – Cases of eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss) developing in temporal relationship with the use of
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         have been reported, although the coincident reduction in glucocorticoid therapy must also be considered as a possible contributing factor in expression of the disease. Reports about this association are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/4363.html" rel="external">
          "Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)", section on 'Omalizumab'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          Omalizumab
         </a>
         has also been administered as an investigational therapy for the treatment of EGPA. (See
         <a class="local">
          'Anti-IgE therapy in other diseases'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4346.html" rel="external">
          "Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Treatment and prognosis", section on 'Less common therapies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Susceptibility to parasitic infection
         </strong>
         – Concerns that reducing IgE might impair immunity to parasitic infections were addressed experimentally in mice infected with
         <em>
          Strongyloides
         </em>
         and
         <em>
          Schistosoma
         </em>
         . Surprisingly, animals treated with anti-IgE therapy showed increased rather than decreased elimination of parasites [
         <a href="#rid126">
          126,127
         </a>
         ]. However, a randomized trial of 137 people with allergic asthma who were at high risk for helminth infection and received
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         or placebo for one year found a trend toward more infections in the omalizumab subjects, although the difference was not statistically significant [
         <a href="#rid128">
          128
         </a>
         ]. Response to appropriate anti-geohelminth treatment of infection was not different between treatment groups. This issue might warrant further investigation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Malignancy
         </strong>
         – Early data raised the possibility of an association between
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         treatment and malignancy, although this was not supported by subsequent analyses. The manufacturer submitted an initial report to the FDA in 2003 of adverse effects in all preclinical and clinical studies [
         <a href="#rid108">
          108,109
         </a>
         ]. This reported that there were 16 malignancies (0.4 percent) in the omalizumab group and 2 (0.1 percent) in the control group, representing a 0.3 percentage point increase in the rate of malignancy per year. These were largely solid tumors that varied in location and cell type.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In 2012, a systematic review of 32 randomized trials identified 14 malignancies in 4254 omalizumab-treated patients and 11 in 3178 placebo-treated patients. No patterns in the type or histologic characteristics were detected, making it unlikely that there is an increased risk of malignancy with
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         treatment [
         <a href="#rid129">
          129
         </a>
         ]. A prospective cohort study published in 2014, in which exposed and nonexposed patients were followed for five years, also found no increase in malignancy risk [
         <a href="#rid130">
          130
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Theoretical concerns
         </strong>
         – There are theoretical concerns about the therapy that have
         <strong>
          not
         </strong>
         been observed with clinical use. These include the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Thrombocytopenia was noted in experiments in which cynomolgus monkeys received 3 to 27 times the maximum human clinical dose but has not been a significant problem in reported human trials [
         <a href="#rid111">
          111
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Loss of effect with continued treatment has not been observed.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1798184980">
         <span class="h1">
          SPECIAL POPULATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Safety in pregnancy and lactation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initiation of
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         in pregnant women is not recommended, although if a woman becomes pregnant while receiving omalizumab, it is suggested that therapy can be continued if the benefits are estimated to outweigh the potential harms. IgG crosses the placenta, so the fetus of a woman receiving omalizumab would be exposed to the drug. Studies of the safety of omalizumab in pregnancy are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/554.html" rel="external">
          "Management of asthma during pregnancy", section on 'Anti-immunoglobulin E'
         </a>
         .)
        </p>
        <p>
         IgG is excreted into human milk, so it would be expected that a breastfeeding infant would be exposed to
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         to some degree. Data in humans are not available [
         <a href="#rid131">
          131
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H253018700">
         <span class="h2">
          Safety in children between the ages of 6 and 11 years
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies in this patient population with asthma did not identify significant increased risks of serious adverse events, including cardiovascular problems or malignancy. However, long-term experience in the pediatric population is limited.
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          OTHER NOVEL STRATEGIES TO REDUCE IgE
         </span>
        </p>
        <p class="headingAnchor" id="H378246680">
         <span class="h2">
          Higher-affinity anti-IgE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Another anti-IgE monoclonal antibody, ligelizumab, with approximately 50-fold greater affinity for IgE, has been shown to inhibit allergen-induced skin test responses and reduce IgE levels to a greater degree than
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         [
         <a href="#rid132">
          132,133
         </a>
         ]. However, in a field study of asthma patients, it did not have any better effects than omalizumab, and further development for asthma has been discontinued [
         <a href="#rid134">
          134
         </a>
         ]. Ligelizumab is being evaluated for the treatment of chronic spontaneous urticaria.
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h2">
          Cytokine modulators
         </span>
         <span class="headingEndMark">
          —
         </span>
         IgE synthesis is suppressed by inhibition of the cytokines interleukin (IL)-4 or IL-13, which are needed for class-switching. IgE production is also inhibited by the cytokines interferon-gamma and IL-12, which switch the balance from T helper type 2 toward T helper type 1 [
         <a href="#rid4">
          4
         </a>
         ]. Several efforts have been made to influence IgE production at these upstream steps [
         <a href="#rid135">
          135-140
         </a>
         ].
         <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">
          Dupilumab
         </a>
         , an anti-IL-4-alpha receptor monoclonal antibody, has demonstrated some suppression of IgE levels of unclear clinical significance and has exhibited positive results in trials for atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis [
         <a href="#rid141">
          141-144
         </a>
         ]. Dupilumab is approved for the treatment of severe atopic dermatitis in patients age 18 years and above, as well as for chronic rhinosinusitis with nasal polyposis. (See
         <a class="medical medical_review" href="/z/d/html/121195.html" rel="external">
          "Chronic rhinosinusitis with nasal polyposis: Management and prognosis", section on 'Anti-IL-4RA (dupilumab)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1730.html" rel="external">
          "Treatment of atopic dermatitis (eczema)", section on 'Dupilumab'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          IgE in asthma
         </strong>
         – Immunoglobulin E (IgE) plays a central role in the mechanism of immediate bronchoconstriction and the influx of inflammatory cells in allergic asthmatic patients after inhalation of allergen. Most asthmatic patients are atopic and have elevated circulating IgE concentrations when levels are adjusted for age. (See
         <a class="local">
          'Role of IgE in asthma'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanism of
         </strong>
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         – Omalizumab is a recombinant humanized IgG1 monoclonal antibody that binds circulating IgE, forming immune complexes that are subsequently cleared by the hepatic reticuloendothelial system  (
         <a class="graphic graphic_figure graphicRef59320" href="/z/d/graphic/59320.html" rel="external">
          figure 1
         </a>
         ). This binding inhibits the attachment of IgE to IgE receptors on mast cells, basophils, and other cell types, thereby reducing surface IgE receptor levels and the ability of these cells to be activated by allergens. (See
         <a class="local">
          'Omalizumab therapy in asthma'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications in asthma
         </strong>
         –
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          Omalizumab
         </a>
         is approved for use as an add-on therapy in patients six years of age and above with inadequately controlled moderate-to-severe asthma despite the use of inhaled glucocorticoid therapy at appropriate doses. The
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fginasthma.org%2Fgina-reports%2F&amp;token=Py93ynnU9f3vyGk1a5XWKiW%2FmuhscuPY09dfrBoFhX2Q3GzgeLrGYBihxgI54Axy&amp;TOPIC_ID=545" target="_blank">
          2021 Global Initiative for Asthma (GINA) guidelines
         </a>
         recommended that omalizumab be considered as adjunctive therapy in step 5 care for patients with severe persistent asthma. (See
         <a class="local">
          'Indications and patient selection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient selection
         </strong>
         – In the United States, patients receiving
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          omalizumab
         </a>
         for asthma should be six years of age or older, have total serum IgE levels between 30 and 700 international units/mL in adults and 30 and 1300 international units/mL in 6- to 11-year-old children, and have evidence of sensitization to a perennial aeroallergen either by allergen skin testing or in vitro IgE testing. However, other biomarkers or clinical features that reliably identify patients who are likely to respond to therapy have not been definitively identified, but pretreatment blood eosinophil counts might prove useful. (See
         <a class="local">
          'Indications and patient selection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Impact on asthma
         </strong>
         Randomized trials of patients with moderate and severe persistent asthma showed that anti-IgE therapy significantly reduces severe exacerbations. Many patients can also significantly reduce their need for inhaled glucocorticoids. (See
         <a class="local">
          'Efficacy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Use in other disorders
         </strong>
         –
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          Omalizumab
         </a>
         is also effective for the treatment of chronic urticaria that is refractory to antihistamine therapy and several other disorders. (See
         <a class="local">
          'Anti-IgE therapy in other diseases'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Administration
         </strong>
         –
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          Omalizumab
         </a>
         is administered by subcutaneous injection. No specific laboratory tests are suggested for monitoring patients who are responding (or not responding) clinically to anti-IgE therapy. Total serum IgE levels are not helpful, because these do not distinguish free IgE from IgE complexed to the drug, and total IgE levels typically increase three- to sixfold on therapy. (See
         <a class="local">
          'Administration'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         –
         <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">
          Omalizumab
         </a>
         is generally well-tolerated. Anaphylaxis occurs in approximately 1 to 2 per 1000 patients and can develop after any dose, including the first one, or have a delayed onset or a protracted course. Professional allergy societies in the United States have proposed observing patients for two hours after the initial three doses and for 30 minutes after each subsequent dose. (See
         <a class="local">
          'Adverse effects'
         </a>
         above and
         <a class="local">
          'Hypersensitivity reactions'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Corry DB, Kheradmand F. Induction and regulation of the IgE response. Nature 1999; 402:B18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burrows B, Martinez FD, Halonen M, et al. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989; 320:271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gauchat JF, Lebman DA, Coffman RL, et al. Structure and expression of germline epsilon transcripts in human B cells induced by interleukin 4 to switch to IgE production. J Exp Med 1990; 172:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Vries JE, Carballido JM, Aversa G. Receptors and cytokines involved in allergic TH2 cell responses. J Allergy Clin Immunol 1999; 103:S492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turner H, Kinet JP. Signalling through the high-affinity IgE receptor Fc epsilonRI. Nature 1999; 402:B24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsicopoulos A, Joseph M. The role of CD23 in allergic disease. Clin Exp Allergy 2000; 30:602.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinmayr G, Weiland SK, Björkstén B, et al. Atopic sensitization and the international variation of asthma symptom prevalence in children. Am J Respir Crit Care Med 2007; 176:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sears MR, Burrows B, Flannery EM, et al. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med 1991; 325:1067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arbes SJ Jr, Gergen PJ, Vaughn B, Zeldin DC. Asthma cases attributable to atopy: results from the Third National Health and Nutrition Examination Survey. J Allergy Clin Immunol 2007; 120:1139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heymann PW, Carper HT, Murphy DD, et al. Viral infections in relation to age, atopy, and season of admission among children hospitalized for wheezing. J Allergy Clin Immunol 2004; 114:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Humbert M, Menz G, Ying S, et al. The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences. Immunol Today 1999; 20:528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zieg G, Lack G, Harbeck RJ, et al. In vivo effects of glucocorticoids on IgE production. J Allergy Clin Immunol 1994; 94:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jabara HH, Brodeur SR, Geha RS. Glucocorticoids upregulate CD40 ligand expression and induce CD40L-dependent immunoglobulin isotype switching. J Clin Invest 2001; 107:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol 1993; 151:2623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fick RB Jr. Anti-IgE as novel therapy for the treatment of asthma. Curr Opin Pulm Med 1999; 5:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haselden BM, Kay AB, Larché M. Peptide-mediated immune responses in specific immunotherapy. Int Arch Allergy Immunol 2000; 122:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buhl R. Anti-IgE antibodies for the treatment of asthma. Curr Opin Pulm Med 2005; 11:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           The Pink Sheet. FDC Reports. Chevy Chase, MD. 2003; 65:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Omalizumab (Xolair): an anti-IgE antibody for asthma. Med Lett Drugs Ther 2003; 45:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Busse W, Spector S, Rosén K, et al. High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. J Allergy Clin Immunol 2013; 132:485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casale TB, Chipps BE, Rosén K, et al. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy 2018; 73:490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casale TB, Luskin AT, Busse W, et al. Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study. J Allergy Clin Immunol Pract 2019; 7:156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bousquet J, Wenzel S, Holgate S, et al. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004; 125:1378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011; 364:1005.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johansson SG, Nopp A, Oman H, et al. The size of the disease relevant IgE antibody fraction in relation to 'total-IgE' predicts the efficacy of anti-IgE (Xolair) treatment. Allergy 2009; 64:1472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ankerst J, Nopp A, Johansson SG, et al. Xolair is effective in allergics with a low serum IgE level. Int Arch Allergy Immunol 2010; 152:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olivieri M, Biscardo CA, Turri S, Perbellini L. Omalizumab in persistent severe bakers' asthma. Allergy 2008; 63:790.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leynadier F, Doudou O, Gaouar H, et al. Effect of omalizumab in health care workers with occupational latex allergy. J Allergy Clin Immunol 2004; 113:360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pillai P, Chan YC, Wu SY, et al. Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma. Eur Respir J 2016; 48:1593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia G, Magnan A, Chiron R, et al. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest 2013; 144:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teach SJ, Gill MA, Togias A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clin Immunol 2015; 136:1476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Esquivel A, Busse WW, Calatroni A, et al. Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma. Am J Respir Crit Care Med 2017; 196:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Easthope S, Jarvis B. Omalizumab. Drugs 2001; 61:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacGlashan DW Jr. Releasability of human basophils: cellular sensitivity and maximal histamine release are independent variables. J Allergy Clin Immunol 1993; 91:605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacGlashan DW Jr, Bochner BS, Adelman DC, et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997; 158:1438.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saini SS, MacGlashan DW Jr, Sterbinsky SA, et al. Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol 1999; 162:5624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beck LA, Marcotte GV, MacGlashan D, et al. Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol 2004; 114:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gomez G, Jogie-Brahim S, Shima M, Schwartz LB. Omalizumab reverses the phenotypic and functional effects of IgE-enhanced Fc epsilonRI on human skin mast cells. J Immunol 2007; 179:1353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacGlashan DW Jr, Savage JH, Wood RA, Saini SS. Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors. J Allergy Clin Immunol 2012; 130:1130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savage JH, Courneya JP, Sterba PM, et al. Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. J Allergy Clin Immunol 2012; 130:1123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin H, Boesel KM, Griffith DT, et al. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol 2004; 113:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ong YE, Menzies-Gow A, Barkans J, et al. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. J Allergy Clin Immunol 2005; 116:558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corren J, Shapiro G, Reimann J, et al. Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy. J Allergy Clin Immunol 2008; 121:506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walker S, Monteil M, Phelan K, et al. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev 2006; :CD003559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011; 139:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boulet LP, Chapman KR, Côté J, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997; 155:1835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Djukanović R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004; 170:583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18:254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108:184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997; 155:1828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noga O, Hanf G, Brachmann I, et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol 2006; 117:1493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oliver JM, Tarleton CA, Gilmartin L, et al. Reduced FcepsilonRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy. Int Arch Allergy Immunol 2010; 151:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holgate ST, Chuchalin AG, Hébert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34:632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 2009; 124:1210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 2014; :CD003559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodrigo GJ, Neffen H. Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents. Pediatr Allergy Immunol 2015; 26:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011; 154:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brodlie M, McKean MC, Moss S, Spencer DA. The oral corticosteroid-sparing effect of omalizumab in children with severe asthma. Arch Dis Child 2012; 97:604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gill MA, Bajwa G, George TA, et al. Counterregulation between the FcepsilonRI pathway and antiviral responses in human plasmacytoid dendritic cells. J Immunol 2010; 184:5999.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kantor DB, Stenquist N, McDonald MC, et al. Rhinovirus and serum IgE are associated with acute asthma exacerbation severity in children. J Allergy Clin Immunol 2016; 138:1467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gill MA, Liu AH, Calatroni A, et al. Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab. J Allergy Clin Immunol 2018; 141:1735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corren J, Wood RA, Patel D, et al. Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge. J Allergy Clin Immunol 2011; 127:398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis LA. Omalizumab: a novel therapy for allergic asthma. Ann Pharmacother 2004; 38:1236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamilton RG, Marcotte GV, Saini SS. Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy. J Immunol Methods 2005; 303:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korn S, Haasler I, Fliedner F, et al. Monitoring free serum IgE in severe asthma patients treated with omalizumab. Respir Med 2012; 106:1494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamilton RG. Accuracy of US Food and Drug Administration-cleared IgE antibody assays in the presence of anti-IgE (omalizumab). J Allergy Clin Immunol 2006; 117:759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Massanari M, Holgate ST, Busse WW, et al. Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. Respir Med 2010; 104:188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Çildağ S, Şentürk T. The effect of omalizumab treatment on IgE and other immunoglobulin levels in patients with chronic spontaneous urticaria and its association with treatment response. Postepy Dermatol Alergol 2018; 35:516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           The Pink Sheet. FDC Reports. Chevy Chase, MD. 2003; 65:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol 2004; 114:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu AC, Paltiel AD, Kuntz KM, et al. Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. J Allergy Clin Immunol 2007; 120:1146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dal Negro RW, Pradelli L, Tognella S, et al. Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy. Eur Ann Allergy Clin Immunol 2011; 43:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Costello RW, Long DA, Gaine S, et al. Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs. Ir J Med Sci 2011; 180:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suzuki C, Lopes da Silva N, Kumar P, et al. Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting. J Med Econ 2017; 20:832.
          </a>
         </li>
         <li class="breakAll">
          Xolair. 1-866-4-XOLAIR.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asai N, Ohkuni Y, Komatsu A, et al. Severe persistent asthma responsive to off-label use of omalizumab despite high and low levels of total serum IgE. J Bras Pneumol 2011; 37:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sugino Y, Sanda R, Takagi Y, et al. [A case of severe asthma responsive to omalizumab treatment despite a low serum IgE level and lack of sensitized allergens]. Arerugi 2010; 59:1572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fahy JV, Cockcroft DW, Boulet LP, et al. Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am J Respir Crit Care Med 1999; 160:1023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corne J, Djukanovic R, Thomas L, et al. The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. J Clin Invest 1997; 99:879.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fahy JV. Reducing IgE levels as a strategy for the treatment of asthma. Clin Exp Allergy 2000; 30 Suppl 1:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barnes PJ. Anti-IgE therapy in asthma: rationale and therapeutic potential. Int Arch Allergy Immunol 2000; 123:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghazanfar MN, Thomsen SF. Home self-administration of omalizumab. J Dermatolog Treat 2018; 29:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menzella F, Facciolongo N, Castagnetti C, et al. Omalizumab: when the non-responder is a late-responder. Eur Ann Allergy Clin Immunol 2009; 41:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Slavin RG, Ferioli C, Tannenbaum SJ, et al. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. J Allergy Clin Immunol 2009; 123:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Humbert M, Bourdin A, Taillé C, et al. Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of paediatric and adult asthma patients. Eur Respir J 2022; 60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vennera MDC, Sabadell C, Picado C, Spanish Omalizumab Registry. Duration of the efficacy of omalizumab after treatment discontinuation in 'real life' severe asthma. Thorax 2018; 73:782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nopp A, Johansson SG, Adédoyin J, et al. After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy 2010; 65:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lowe PJ, Renard D. Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE. Br J Clin Pharmacol 2011; 72:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leung DY, Sampson HA, Yunginger JW, et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003; 348:986.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andorf S, Purington N, Block WM, et al. Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial. Lancet Gastroenterol Hepatol 2018; 3:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Kalil J. Three months' administration of anti-IgE to a patient with Churg-Strauss syndrome. J Allergy Clin Immunol 2007; 119:1279; author reply 1279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Penn R, Mikula S. The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study. Am J Rhinol 2007; 21:428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fairley JA, Baum CL, Brandt DS, Messingham KA. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol 2009; 123:704.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pérez-de-Llano LA, Vennera MC, Parra A, et al. Effects of omalizumab in Aspergillus-associated airway disease. Thorax 2011; 66:539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sampson HA, Leung DY, Burks AW, et al. A phase II, randomized, double‑blind, parallel‑group, placebo‑controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol 2011; 127:1309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lehmann S, Pfannenstiel C, Friedrichs F, et al. Omalizumab: a new treatment option for allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Ther Adv Respir Dis 2014; 8:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jat KR, Walia DK, Khairwa A. Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev 2018; 3:CD010288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 106:253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casale TB, Bernstein IL, Busse WW, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997; 100:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mankad VS, Burks AW. Omalizumab : other indications and unanswered questions. Clin Rev Allergy Immunol 2005; 29:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kopp MV, Stenglein S, Kamin W, et al. Omalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential in vitro parameter to monitor therapeutic effects. Pediatr Allergy Immunol 2007; 18:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casale TB, Condemi J, LaForce C, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001; 286:2956.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kontou-Fili K. High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 2008; 63:376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Massanari M, Nelson H, Casale T, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 2010; 125:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casale TB, Busse WW, Kline JN, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006; 117:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stock P, Rolinck-Werninghaus C, Wahn U, Hamelmann E. The role of anti-IgE therapy in combination with allergen specific immunotherapy for seasonal allergic rhinitis. BioDrugs 2007; 21:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Occasi F, Duse M, Nebbioso M, et al. Vernal keratoconjunctivitis treated with omalizumab: A case series. Pediatr Allergy Immunol 2017; 28:503.
          </a>
         </li>
         <li class="breakAll">
          Genentech, Inc. Omalizumab (Xolair) Review of clinical safety data. www.fda.gov/ohrms/dockets/ac/03/briefing/3952B1_02_FDA-Xolair-Safety.pdf (Accessed on April 27, 2006).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deniz YM, Gupta N. Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody. Clin Rev Allergy Immunol 2005; 29:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin RY, Rodriguez-Baez G, Bhargave GA. Omalizumab-associated anaphylactic reactions reported between January 2007 and June 2008. Ann Allergy Asthma Immunol 2009; 103:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corren J, Casale TB, Lanier B, et al. Safety and tolerability of omalizumab. Clin Exp Allergy 2009; 39:788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cox L, Platts-Mills TA, Finegold I, et al. American Academy of Allergy, Asthma &amp; Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007; 120:1373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cox L, Lieberman P, Wallace D, et al. American Academy of Allergy, Asthma &amp; Immunology/American College of Allergy, Asthma &amp; Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report. J Allergy Clin Immunol 2011; 128:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Price KS, Hamilton RG. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc 2007; 28:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lieberman PL, Umetsu DT, Carrigan GJ, Rahmaoui A. Anaphylactic reactions associated with omalizumab administration: Analysis of a case-control study. J Allergy Clin Immunol 2016; 138:913.
          </a>
         </li>
         <li class="breakAll">
          United States Food and Drug Administration. 2007 Safety alerts for drug, biologics, medical devices, and dietary supplements. www.fda.gov/medwatch/safety/2007/safety07.htm#Xolair (Accessed on January 29, 2008).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Limb SL, Starke PR, Lee CE, Chowdhury BA. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol 2007; 120:1378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lieberman P, Rahmaoui A, Wong DA. The safety and interpretability of skin tests with omalizumab. Ann Allergy Asthma Immunol 2010; 105:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Owens G, Petrov A. Successful desensitization of three patients with hypersensitivity reactions to omalizumab. Curr Drug Saf 2011; 6:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dreyfus DH, Randolph CC. Characterization of an anaphylactoid reaction to omalizumab. Ann Allergy Asthma Immunol 2006; 96:624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pilette C, Coppens N, Houssiau FA, Rodenstein DO. Severe serum sickness-like syndrome after omalizumab therapy for asthma. J Allergy Clin Immunol 2007; 120:972.
          </a>
         </li>
         <li class="breakAll">
          Omalizumab (marketed as Xolair) - Early communication about an ongoing safety review. Available on the website of the U.S. Department of Health and Human Services. www.accessdata.fda.gov/scripts/cder/drugsatfda/ (Accessed on August 19, 2009).
         </li>
         <li class="breakAll">
          United States Food and Drug Administration (FDA) release. http://www.fda.gov/Drugs/DrugSafety/ucm414911.htm?source=govdelivery&amp;utm_medium=email&amp;utm_source=govdelivery (Accessed on September 30, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iribarren C, Rahmaoui A, Long AA, et al. Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma. J Allergy Clin Immunol 2017; 139:1489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pollevick ME, Xu KY, Mhango G, et al. The Relationship Between Asthma and Cardiovascular Disease: An Examination of the Framingham Offspring Study. Chest 2021; 159:1338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korenaga M, Watanabe N, Tada I. Effects of anti-IgE monoclonal antibody on a primary infection of Strongyloides ratti in mice. Parasitol Res 1991; 77:362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amiri P, Haak-Frendscho M, Robbins K, et al. Anti-immunoglobulin E treatment decreases worm burden and egg production in Schistosoma mansoni-infected normal and interferon gamma knockout mice. J Exp Med 1994; 180:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cruz AA, Lima F, Sarinho E, et al. Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin Exp Allergy 2007; 37:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Busse W, Buhl R, Fernandez Vidaurre C, et al. Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol 2012; 129:983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Long A, Rahmaoui A, Rothman KJ, et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol 2014; 134:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grunewald S, Jank A. New systemic agents in dermatology with respect to fertility, pregnancy, and lactation. J Dtsch Dermatol Ges 2015; 13:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arm JP, Bottoli I, Skerjanec A, et al. Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. Clin Exp Allergy 2014; 44:1371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gauvreau GM, Arm JP, Boulet LP, et al. Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. J Allergy Clin Immunol 2016; 138:1051.
          </a>
         </li>
         <li class="breakAll">
          https://www.novartis.com/our-work/research-development/clinical-pipeline (Accessed on October 25, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borish LC, Nelson HS, Lanz MJ, et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999; 160:1816.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ichinose M, Barnes PJ. Cytokine-directed therapy in asthma. Curr Drug Targets Inflamm Allergy 2004; 3:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007; 370:1422.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365:1088.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bryan SA, O'Connor BJ, Matti S, et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356:2149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boguniewicz M, Martin RJ, Martin D, et al. The effects of nebulized recombinant interferon-gamma in asthmatic airways. J Allergy Clin Immunol 1995; 95:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pauwels B, Jonstam K, Bachert C. Emerging biologics for the treatment of chronic rhinosinusitis. Expert Rev Clin Immunol 2015; 11:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hamilton JD, Suárez-Fariñas M, Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 2014; 134:1293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014; 371:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368:2455.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 545 Version 40.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10586891" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Induction and regulation of the IgE response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2911321" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Association of asthma with serum IgE levels and skin-test reactivity to allergens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1695667" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Structure and expression of germline epsilon transcripts in human B cells induced by interleukin 4 to switch to IgE production.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10329853" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Receptors and cytokines involved in allergic TH2 cell responses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10586892" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Signalling through the high-affinity IgE receptor Fc epsilonRI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10792350" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The role of CD23 in allergic disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17575099" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Atopic sensitization and the international variation of asthma symptom prevalence in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1891008" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17889931" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Asthma cases attributable to atopy: results from the Third National Health and Nutrition Examination Survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15316497" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Viral infections in relation to age, atopy, and season of admission among children hospitalized for wheezing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10529782" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8064074" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : In vivo effects of glucocorticoids on IgE production.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11160161" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Glucocorticoids upregulate CD40 ligand expression and induce CD40L-dependent immunoglobulin isotype switching.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8360482" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Humanization of an antibody directed against IgE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10813254" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Anti-IgE as novel therapy for the treatment of asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10971112" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Peptide-mediated immune responses in specific immunotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15591885" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Anti-IgE antibodies for the treatment of asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Chevy Chase, MD
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12915804" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Omalizumab (Xolair): an anti-IgE antibody for asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23591271" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28859263" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29800752" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15078749" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21410369" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19393000" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The size of the disease relevant IgE antibody fraction in relation to 'total-IgE' predicts the efficacy of anti-IgE (Xolair) treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19940508" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Xolair is effective in allergics with a low serum IgE level.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18445199" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Omalizumab in persistent severe bakers' asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14767458" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Effect of omalizumab in health care workers with occupational latex allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27824606" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23579324" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26518090" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28608756" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11270941" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Omalizumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7679683" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Releasability of human basophils: cellular sensitivity and maximal histamine release are independent variables.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9013989" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10228046" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15356552" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Omalizumab-induced reductions in mast cell Fce psilon RI expression and function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17617628" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Omalizumab reverses the phenotypic and functional effects of IgE-enhanced Fc epsilonRI on human skin mast cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22800400" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22800401" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14767445" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16159624" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18269927" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16625585" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Anti-IgE for chronic asthma in adults and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20688929" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9196083" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15172898" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11529281" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11496232" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9196082" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16751018" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19844128" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Reduced FcepsilonRI-mediated release of asthma-promoting cytokines and chemokines from human basophils during omalizumab therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15080818" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19910033" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24414989" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Omalizumab for asthma in adults and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25963882" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21536936" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22685051" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : The oral corticosteroid-sparing effect of omalizumab in children with severe asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20410486" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Counterregulation between the FcepsilonRI pathway and antiviral responses in human plasmacytoid dendritic cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27474123" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Rhinovirus and serum IgE are associated with acute asthma exacerbation severity in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28870461" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21281870" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15187202" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Omalizumab: a novel therapy for allergic asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16045925" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22884459" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Monitoring free serum IgE in severe asthma patients treated with omalizumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16630931" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Accuracy of US Food and Drug Administration-cleared IgE antibody assays in the presence of anti-IgE (omalizumab).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19846286" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Effect of omalizumab on peripheral blood eosinophilia in allergic asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30429712" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : The effect of omalizumab treatment on IgE and other immunoglobulin levels in patients with chronic spontaneous urticaria and its association with treatment response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Chevy Chase, MD
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15316501" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17904628" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21608372" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21557095" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28532191" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28532191" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21881749" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Severe persistent asthma responsive to off-label use of omalizumab despite high and low levels of total serum IgE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21119303" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : [A case of severe asthma responsive to omalizumab treatment despite a low serum IgE level and lack of sensitized allergens].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10471635" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9062345" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10849469" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Reducing IgE levels as a strategy for the treatment of asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11112855" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Anti-IgE therapy in asthma: rationale and therapeutic potential.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28604125" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Home self-administration of omalizumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20101930" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Omalizumab: when the non-responder is a late-responder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19130931" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35618272" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of paediatric and adult asthma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29079610" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Duration of the efficacy of omalizumab after treatment discontinuation in 'real life' severe asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19796193" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : After 6 years with Xolair; a 3-year withdrawal follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21392073" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12637608" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Effect of anti-IgE therapy in patients with peanut allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29242014" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Anti-IgE treatment with oral immunotherapy in multifood allergic participants: a double-blind, randomised, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17349685" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Three months' administration of anti-IgE to a patient with Churg-Strauss syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17882911" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19152970" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21398373" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Effects of omalizumab in Aspergillus-associated airway disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21397314" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : A phase II, randomized, double‑blind, parallel‑group, placebo‑controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25150265" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Omalizumab: a new treatment option for allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29551015" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10932067" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9257795" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16222081" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Omalizumab : other indications and unanswered questions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17680911" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Omalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential in vitro parameter to monitor therapeutic effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11743836" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18269681" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20159249" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16387596" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18020623" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : The role of anti-IgE therapy in combination with allergen specific immunotherapy for seasonal allergic rhinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28543949" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Vernal keratoconjunctivitis treated with omalizumab: A case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28543949" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Vernal keratoconjunctivitis treated with omalizumab: A case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16222082" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19927545" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Omalizumab-associated anaphylactic reactions reported between January 2007 and June 2008.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19302249" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Safety and tolerability of omalizumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17996286" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : American Academy of Allergy, Asthma&amp;Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21531014" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : American Academy of Allergy, Asthma&amp;Immunology/American College of Allergy, Asthma&amp;Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17619560" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27236498" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Anaphylactic reactions associated with omalizumab administration: Analysis of a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27236498" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Anaphylactic reactions associated with omalizumab administration: Analysis of a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17936893" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21130393" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : The safety and interpretability of skin tests with omalizumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22424542" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Successful desensitization of three patients with hypersensitivity reactions to omalizumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16680936" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Characterization of an anaphylactoid reaction to omalizumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17716723" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Severe serum sickness-like syndrome after omalizumab therapy for asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17716723" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Severe serum sickness-like syndrome after omalizumab therapy for asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17716723" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Severe serum sickness-like syndrome after omalizumab therapy for asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27639934" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33316236" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : The Relationship Between Asthma and Cardiovascular Disease: An Examination of the Framingham Offspring Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1866426" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Effects of anti-IgE monoclonal antibody on a primary infection of Strongyloides ratti in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8006599" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Anti-immunoglobulin E treatment decreases worm burden and egg production in Schistosoma mansoni-infected normal and interferon gamma knockout mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17250692" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22365654" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Omalizumab and the risk of malignancy: results from a pooled analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24679845" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25819232" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : New systemic agents in dermatology with respect to fertility, pregnancy, and lactation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25200415" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27185571" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27185571" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10588591" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15379594" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Cytokine-directed therapy in asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17950857" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21812663" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Lebrikizumab treatment in adults with asthma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11191543" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7822655" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : The effects of nebulized recombinant interferon-gamma in asthmatic airways.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25651905" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Emerging biologics for the treatment of chronic rhinosinusitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25482871" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25006719" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23688323" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Dupilumab in persistent asthma with elevated eosinophil levels.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
